P585: IMPACT OF MYELOID MUTATION PROFILE ON PCR RESPONSES AND SURVIVAL IN PATIENTS WITH CORE-BINDING FACTOR AML TREATED WITH FLAG BASED REGIMES

Bibliographic Details
Main Authors:	Jayastu Senapati, Aram Bidikian, Farhad Ravandi, Tapan Kadia, Courtney Dinardo, Guillermo Garcia-Manero, Naval Daver, Naveen Pemmaraju, Elias Jabbour, Mark Brandt, Gautam Borthakur
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000969244.62092.d4

Similar Items

P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND
by: Daniel Nguyen, et al.
Published: (2023-08-01)

Acute myeloid leukemia: current progress and future directions
by: Hagop Kantarjian, et al.
Published: (2021-02-01)

P509: THE IMPACT OF THE NUMBER OF RAS MUTATIONS IN THE OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED FRONTLINE AT A SINGLE INSTITUTION.
by: Mahesh Swaminathan, et al.
Published: (2023-08-01)

P575: IMPACT OF MOLECULAR RESPONSE AND CHEMOTHERAPY REGIMEN ON OUTCOMES IN CORE BINDING FACTOR AML
by: J. Senapati, et al.
Published: (2022-06-01)

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
by: Ahmad S. Alotaibi, et al.
Published: (2020-10-01)

P500: SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Jayastu Senapati, et al.
Published: (2023-08-01)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
by: Musa Yilmaz, et al.
Published: (2022-05-01)

Resistance to targeted therapies: delving into FLT3 and IDH
by: Sai Prasad Desikan, et al.
Published: (2022-06-01)

P497: PROGNOSTIC IMPACT OF RAS AND C-KIT MUTATIONS (SINGLE VS. MULTIPLE) IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA TREATED WITH FLUDARABINE, CYTARABINE, G-CSF (FLAG) BASED REGIMEN
by: T. Abuasab, et al.
Published: (2022-06-01)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
by: Musa Yilmaz, et al.
Published: (2020-10-01)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
by: Danielle Hammond, et al.
Published: (2023-09-01)

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
by: Kamal Chamoun, et al.
Published: (2019-01-01)

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
by: Nicholas J. Short, et al.
Published: (2022-01-01)

P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS
by: S. Venugopal, et al.
Published: (2022-06-01)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
by: Alexandre Bazinet, et al.
Published: (2023-08-01)

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells
by: Warren Fiskus, et al.
Published: (2021-05-01)

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study
by: Patrick K. Reville, et al.
Published: (2021-03-01)

P377: A PHASE II TRIAL OF MINI-HYPER-CVD WITH VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
by: Fadi Haddad, et al.
Published: (2023-08-01)

Extramedullary Acute Myeloid Leukemia (AML): Leukemic Pleural Effusion, Case Report and Review of the Literature
by: Naveen ePemmaraju, et al.
Published: (2014-06-01)

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, C, et al.
Published: (2022)

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)
by: F. Ong, et al.
Published: (2022-06-01)

P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA
by: Guillermo Montalban-Bravo, et al.
Published: (2023-08-01)

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
by: Jayastu Senapati, et al.
Published: (2023-06-01)

Maintenance Therapy in AML
by: Patrick K. Reville, et al.
Published: (2021-02-01)

P495: PHASE 2 STUDY OF ASTX727 (DECITABINE/CEDAZURIDINE) PLUS VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR PREVIOUSLY UNTREATED, ELDERLY PATIENTS UNFIT FOR CHEMOTHERAPY
by: T. Abuasab, et al.
Published: (2022-06-01)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
by: Claudio Cerchione, et al.
Published: (2021-03-01)

Editorial: The Biological Landscape of Immunotherapy in AML
by: Alessandro Isidori, et al.
Published: (2021-04-01)

P373: UPDATES FROM A PHASE II TRIAL OF MINI-HYPER-CVD-INOTUZUMAB WITH OR WITHOUT BLINATUMOMAB IN OLDER PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
by: Fadi Haddad, et al.
Published: (2023-08-01)

P541: OUTCOMES AND MANAGEMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS
by: F. Haddad, et al.
Published: (2022-06-01)

P496: CLINICAL CHARACTERISTICS OF SECONDARY MYELOID NEOPLASMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
by: T. Abuasab, et al.
Published: (2022-06-01)

Immunotherapy in Acute Myeloid Leukemia: Where We Stand
by: Alessandro Isidori, et al.
Published: (2021-05-01)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
by: Nicholas J. Short, et al.
Published: (2023-07-01)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
by: Ghayas C. Issa, et al.
Published: (2021-09-01)

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
by: Warren Fiskus, et al.
Published: (2023-04-01)

P566: IMPACT OF FRONTLINE INDUCTION APPROACH ON POST-STEM CELL TRANSPLANT (SCT) OUTCOMES IN OLDER ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
by: F. Ong, et al.
Published: (2022-06-01)

Acute Myeloid Leukemia (AML) as a model for cancer therapy
by: Farhad eRavandi
Published: (2012-10-01)

P485: AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY
by: Nicholas Short, et al.
Published: (2023-08-01)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
by: Abhishek Maiti, et al.
Published: (2021-02-01)

First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations
by: Naval Daver, et al.
Published: (2020-08-01)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
by: Warren Fiskus, et al.
Published: (2022-01-01)